Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 May 4;19(5):347-348.
doi: 10.1080/15384047.2018.1423926. Epub 2018 Feb 2.

Androgen receptor-independent prostate cancer: an emerging clinical entity

Ilyas Sahin  1 , Anthony E Mega  1 , Benedito A Carneiro  1
Affiliations
Comment

Androgen receptor-independent prostate cancer: an emerging clinical entity

Ilyas Sahin et al. Cancer Biol Ther. .

Abstract

Androgen deprivation therapy remains the backbone of prostate cancer treatment given its pivotal role in the pathogenesis of prostate cancer. The growing knowledge of androgen receptor-independent (i.e. AR-null) prostate cancer cells, however, might advance the treatment paradigm of prostate cancer. Here, we examined the results of two recent studies, published in Cancer Cell by Bluemn and Shukla et al., and their impact in the future management of castration-resistant prostate cancer.

Keywords: Cancer Biology; androgen; castration; independent; medicine; personalized; receptor; resistance.

PubMed Disclaimer

Comment on

  • Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.
    Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS. Bluemn EG, et al. Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003. Cancer Cell. 2017. PMID: 29017058 Free PMC article.
  • Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.
    Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, Xie Y, Chen Y, Wang S, Zhan Y, Li D, Wong EWP, Sboner A, Beltran H, Mosquera JM, Sher J, Cao Z, Wongvipat J, Koche RP, Gopalan A, Zheng D, Rubin MA, Scher HI, Chi P, Chen Y. Shukla S, et al. Cancer Cell. 2017 Dec 11;32(6):792-806.e7. doi: 10.1016/j.ccell.2017.10.008. Epub 2017 Nov 16. Cancer Cell. 2017. PMID: 29153843 Free PMC article.

References

    1. Saraon P, Drabovich AP, Jarvi KA, Diamandis EP. Mechanisms of androgen-independent prostate cancer. EJIFCC. 2014;25(1):42–54. - PMC - PubMed
    1. Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, Xie Y, Chen Y, Wang S, Zhan Y, et al. . Aberrant activation of a gastrointestinal transcriptional circuit in prostate cancer mediates castration resistance. Cancer Cell. 2017;32(6):792–806. doi:10.1016/j.ccell.2017.10.008. - DOI - PMC - PubMed
    1. Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, et al. . Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32(4):474–489 e476. doi:10.1016/j.ccell.2017.09.003. - DOI - PMC - PubMed
    1. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, et al. . Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64(24):9209–9216. doi:10.1158/0008-5472.CAN-04-2442. - DOI - PubMed
    1. Cattrini C, Zanardi E, Vallome G, Cavo A, Cerbone L, Di Meglio A, Fabbroni C, Latocca MM, Rizzo F, Messina C,et al. Targeting androgen-independent pathways: new chances for patients with prostate cancer? Crit Rev Oncol Hematol. 2017;118:42–53. doi:10.1016/j.critrevonc.2017.08.009. - DOI - PubMed

Substances

LinkOut - more resources